| Kitsize | 12x8 |
| Method | ELISA |
| Incubationtime | 2x1h,1x20min. |
| Standardrange | 62-500ng/mL |
| Specimen/Volumes | serum,plasma |
| Substrate/isotope | TMB450nm |
| RegulatoryStatus: | EU:CE |
TheMatriksBiotekSHIKARI®Anti-InfliximabAntibodyELISAisanenzymeimmunoassayforthequantitativedeterminationofantibodiestoinfliximabinhumanserumandplasma.
Infliximab(Remicade®)isachimericmonoclonalantibodyandusedtotreatautoimmunedisorders.Infliximabreducestheamountofactivetmournecrosisfactoralpha(TNFα)onthesurfaceofvariouscelltypes.TNFαisonethekeycytokinesthattriggersandsustainsinflammatoryreactions.Infliximab(Remicade®)isusedforthetreatmentofpsoriasis,Crohn"sdisease,ankylosingspondylitis,psoriatricathritis,rheumatoidarthritis,ulcerativecolitis,andapprovedbytheFDA.ThemajorconcerninusingInfliximabisthepotentialdevelopmentofanti-Infliximabantibodies(ATI),whichinturnmayinterferewithInfliximabefficacyasmainlyjudgedbyobservingtherelapseofsignsandsymptomsofdiesase,necessitatingdose-escalationorpotentiallyendingupthethetreatment.
Inthiscontextdeterminationofanti-InfliximabantibodiesduringtreatmentwithInfliximabplaysanimportantissueduringfollowupoftreatmentregimen.
*distributedbyIBLInternational
